Connect with us

BIOTECH

This Bioceutical Breakthrough May Hold the Key to the NFL’s Deadly CTE Crisis

Published

on

Millionaires are being made by the moment in the medical marijuana industry. Venture capital firms, private equity firms, and even billionaires have gotten in on the action, sending key players to multi-bagger gains overnight.

One only has to remember InMed Pharmaceuticals’ (OTC: IMLFF / IN.V) launch from under a dime to $0.72 in 2017. Or GW Pharmaceuticals’ (NASDAQ: GWPH) sky-high climb when positive phase 3 results were released for Epidiolex to know that investors are churning out fast double, triple and quadruple digits gains.

If you missed those huge rallies, than you’re in luck because GridIron BioNutrients (OTC: GMVP) is just getting started.

With a total of 29 U.S. states legalizing the medical use of cannabis, and 8 with recreational-use laws in place, the market has been abuzz. A new report from the Brightfield Group projected the international market for cannabis to hit $31.4 billion by 2021, showing a compound annual growth rate of 60%.

And those figures could be vastly underestimated when taking into account the full scope of the market potential in development.

Wall Street is even getting in on the action, slating the launch of a new marijuana ETF for later this year or early 2018.  Big tobacco and alcohol are late to the game, but showing signs of an entrance in the near term.  You’re certain to have seen the recent headlines about Philip Morris’ $20 Million investment in Syqe… or Corona’s parent company, Constellation Brands taking a 9.9% share in $2 Billion medical marijuana company, Canopy Growth.

Their early hesitation could mean massive gains for your portfolio as acquisition hungry giants vie for their share of this multi-billion dollar behemoth.

Triggers on the very near horizon, such as coming legalization in the massive Californian and Canadian markets, are driving cannabis to be one of the most promising investments for 2018.  And GridIron Bionutrients (OTC: GMVP) looks to be the best opportunity for this rapidly-growing market.

With an innovative product line, access to capital, and a contract in place with the NFL Alumni Association…All signs point to a winning addition to your portfolio.

 

Are your juices flowing yet?  They should be.  Here’s why…

This IPO May Hold the Key to the NFL’s Deadly CTE Crisis

The NFL is facing a revenue-crushing epidemic.  CTE–the devastating brain disease stalking the NFL has sent dozens of companies scrambling for answers.  Despite $1,500 helmets and neurosurgeons taking brain scans on the sidelines, medical experts say equipment can’t protect athletes enough to prevent lifelong brain damage.

But our newest feature company could save the game and generously reward early shareholders in the process.   GridIron BioNutrients (GMVP) is taking this challenge head on with their groundbreaking sports drink, MVP Nano.

MVP Nano is organically produced and rich with probiotics and trace minerals. And then there’s one extra ingredient medical research has proved to be a neuroprotector—Cannabinoids.

You see, CTE or chronic traumatic encephalopathy is a specific type of permanent brain damage that is caused by multiple blows to the head over time. Doctors used to think it was rare. Then came the high-profile cases of athletes with the distinctive “tau” deposits of CTE getting in trouble or aging before their time.

The cannabinoid formula in MVP Nano is a powerful anti-oxidant, anti-inflammatory, and reduces the buildup of tau proteins.  Drinking it before playing could protect players from the damage on sub-concussive hits to the head.

That’s a groundbreaking feat in its own rite… and one that could make GMVP a coveted acquisition target.

No other company is ready to market a sports-specific Hemp drink. This is how investors find beverage stocks that soar, like VitaminWater, which Coca-Cola acquired for $4.1 billion. That’s approximately 17 times what Vitamin Water’s annual sales were at the time! Musician 50 CENT was a shareholder in Vitamin Water and it’s rumored he made $100 million for his share.

The Amazing Power of Cannabinoids to Cushion the Brain

Scientists have known for years that cannabidiol, the active ingredient in MVP Nano, works powerfully to treat post-traumatic stress disorder, depression, anxiety, seizures and pain. But research just released in 2017 added startling extra dimension.

It turns out that there is now solid proof that cannabidiol is good for the brain.  In the scientific jargon, it is a neuroprotector—and a stronger one than anyone expected.

The latest research shows that it could protect brains from the effects of ischemic strokes and head traumas and reduces the buildup of tau deposits.

With this proof of in hand, GridIron’s MVP Nano is game-ready, formulated, bottled and ready to save the game. But will the image-conscious National Football League approve of a drink with cannabidiol in it?

The National Football League Alumni Association already has!

NFLA represents retired players and markets products through its Pro Football Legends division. It just signed a three-year memorandum of understanding to work with GridIron

As you can see, GridIron isn’t wasting any time breaking into the mainstream sports beverage industry… press was just released introducing a brand new Alkaline Hemp Water to their product line. 

“The formulation of Gridiron Hemp H2O Probiotics™ is a significant development for the Company,” said Darren Long, CEO of Gridiron. “We believe this exceptional product will allow Gridiron to strategically enter the ever-growing Hemp water marketplace at a competitive price point. Gridiron Hemp H2O Probiotics™ is a unique Alkaline water with a pH of 10 infused with Probiotics, Electrolytes and Certified Nano Hemp.” 

NFL Can’t Dodge The Need for Help

The average NFL pro sustains 1,500 blows to the head every season. The worst damage usually doesn’t show up until years later as depression, violent outbursts, aggression, speech disorders, trembling, seizures, difficulty walking, inability to focus, disordered thoughts, and memory loss so severe it looks like advanced Alzheimer’s.

CTE has become a publicity nightmare for the NFL. Former New England Patriot Aaron Hernandez, who committed suicide at age 27, had history of violence including murder… and the worst case of CTE ever seen in a player so young. Four-time Super Bowl champ and Hall of Famer Mike Webster suffered dementia at age 50. His brain showed tau deposits equivalent to being in 25,000 car crashes.

The CTE-football link in today’s game is irrefutable. Researchers at Boston University have found evidence of CTE in 110 of the 111 brains of former NFL players it has autopsied.

Dr. Bennett Omalu, the neurologist who first pinpointed the problem in 2005, puts it starkly …

“If you get to the professional level, I believe there is a 100% chance you have brain damage.”

The NFL has every reason to adopt a protective beverage like MVP Nano immediately.

  • It owes a $1 billion settlement to ex-NFL players suffering CTE, and that will rise unless the damage is stopped.
  • Promising young athletes like Chris Borland are dropping out of the game early to avoid ending up hopelessly brain damaged.
  • And worse for the future, 40% of parents won’t allow their children to learn how to play football in youth leagues and school sports anymore.

Even LeBron James—who was a star wide receiver in high school and recruited by Notre Dame—won’t let his sons play football.

So why wouldn’t the NFL put MVP Nano’s sleek black bottle right out front—Nano MVP, sitting proudly next to that ubiquitous green cooler. It’s the only cannbidiol-enhanced drink formulated by athletes who know nutrition!

GridIron Is Run By Athletes for Athletes

GridIron’s CEO Dan Long is a former pro football player himself. That could be the reason that GridIron is the first and only cannabidiol-enhanced product that we know of to reach a deal with the NFLA.

But Long’s not just a jock. He understands what’s in the bottle and what the right nutrients and bioceuticals can achieve. He has a bachelor’s degree in nutrition from California State University, Long Beach.

GridIron’s Treasurer and director Brian Martinho got his B.S. from San Diego State in Exercise and Nutritional Science. And Timothy Orr, GridIron’s president, has a JD from Gonzaga Law… but before that, he earned his B.A. in Biology from Whitworth University.

Acquisition Potential Is Sky High

If you know the beverage industry, you have probably figured out the real reason to own GridIron BioNutrients (OTC: GMVP)—buyout potential.

The giants of the industry rarely develop new products. They wait for young companies like GridIron to develop and test good ideas, then they pounce, often coughing up 4 to 17 X annual sales. Just the way PepsiCo bought Gatorade and Coke took over PowerAde.

GridIron BioNutrients is still in early development, itself having been only recently acquired by parent company MyCloudz.  That makes it an ideal time to stake out a speculative position for high rewards. Beverage stocks that find a new market can turn into real moonshot for investors—with share value rising as much as 20X like we saw with Samuel Adams or for an astounding 90X catapult, as we saw with Starbucks.

GMVP is staking out an entirely new niche, and you don’t want to miss out on this one.  Take a look at their corporate presentation:

 

Take a look at their corporate presentation:

 

BIOTECH

Insys Therapeutics Inc (NASDAQ:INSY) Issues An Update on CBD Pharmaceuticals and Spray Technology Products

Published

on

By

Insys Therapeutics Inc (NASDAQ:INSY) has issued an update on the naloxone nasal and epinephrine sprays and CBD oral solutions. CEO and President of Insys Therapeutics, Saeed Motahari said the company is focusing on novel drug delivery systems and pharmaceutical grade cannabinoids to drive the growth going forward. It is moving away from opioids. The company is transforming its business strategy to include patient-centric formulations over the past one year. Going forward,  Insys Therapeutics is preparing to submit 6 innovative drug applications in the next 3 years. The company is scheduling two of them in 2019.

An update on the Opioid Related Assets

As per the announced plans,  Insys Therapeutics is scheduling the alternative review of the opioid related assets. As of now, nine firms have entered into a pact with  Insys Therapeutics and are reviewing the confidential information. The company will release an update on this aspect in early 2019.

An Update on the Lifesaving Products

Insys Therapeutics is in the advanced stages of developing the lifesaving investigational products that are based on spray technologies. Its lifesaving products in development include epinephrine nasal spray for anaphylaxis and naloxone nasal spray for the opioid overdose.

The company is also focusing on cannabinoids like CBD oral solution targeting the child absence epilepsy treatment (phase 2), Prader Willi Syndrome (phase 2), infantile spasms (phase 3), and dronabinol inhalation to treat a variety of conditions such as anorexia in patients suffering from cancer.

Insys Therapeutics is conducting a non-clinical toxicity study on naloxone nasal spray and expects to announce the results in March 2019. The company has set the timeframe for the NDA submission in Q1 2019.

Epinephrine nasal spray, which is intended for needle-free delivery, is a substitute to the intramuscular injection. According to the study, it is readily absorbed via the nasal mucosa. The company has obtained FDA nod for fast track designation for the drug in August 2018. It has also provided specific guidelines for filing requirement and clinical development. Insys Therapeutics is optimistic to complete the filing requirements for epinephrine NDA in Q4, 2019. It is subject to successful completion of PK study.

The company has successfully completed a proof of concept study on dronabinol inhalation in September 2018. Insys Therapeutics will arrange a meeting with clinical experts in Q1 2019 to discuss further development for this investigational formulation.

Insys Therapeutics Signs a Pact with Lunatus for Commercializing SUBSYS

Insys Therapeutics has signed a definitive accord with Lunatus for commercializing Subsys in 8 nations in the Middle East. Following the deal, Lunatus will act as an authorized agent and licensee in the UAE, Lebanon, Kuwait, Jordan, Saudi Arabia, Qatar, Oman, and Bahrain.

Continue Reading

BIOTECH

International Consolidated Inc (OTCMKTS:INCC) Pronounces A $5 Million Dollar Institutional Offer

Published

on

International Consolidated Inc (OTCMKTS:INCC) is quite pleased to make the announcement that obtained an institutional offer worth $5 million dollars from the IFG Opportunity Fund LLC. According to a person well conversant with the matter, it happened prior to the company becoming fully reporting.

The business guru is making plans to move ahead and execute its business plan and it is crucial to mention the point that the undertaking served them with about three 3 additional options for funding.

The company’s take on business operations

It was way back in 2004 that the IFG Opportunity Fund, LLC began as a private equity fund set up to make investments in the series of the small growth companies via the PIPE’s which are fundamentally private investments in public equities.

They invest in their own capital and that of course indicates more flexibility as well as a greater competitive advantage at a time when business dynamics tend to be shifting quite fast. Competitive pricing is a point that the business giant takes with much seriousness and market observers have termed that a great way to move about business.

The water-soluble CBD oil super food and expert strategies

The water-soluble CBD oil super food and wellness drinks that are being introduced by BluDog Products are easily absorbed. And they are the perfect alternative for over-the-counter therapeutic option that helps promote well being and relaxation.

Asides from that they play a significant role helping relieve post-sports inflammation not forgetting that the CBD products naturally interact with the anti-inflammatory system of the body and there are no associated side effects.

The Managing Member of BluDog Products LLC Antonio Uccello while moving out of a business conference addressed news reporters telling them that as a company they were quite pleased about getting to the point of providing high quality BluDog Products.

Much has been happening in the recent years, one of the things being the acquisition of the American Nutritional Products Inc. Several market analysts have said that the company is placing itself on the right path in the quest to achieve monumental success in a market characterized with stiff competition.

Continue Reading

BIOTECH

Premier Biomedical Inc (OTCMKTS:BIEI) Searches For Development Partner To Develop Patent Pending Technology

Published

on

Premier Biomedical Inc (OTCMKTS:BIEI) reported that they are actively looking for an associate to advance their patented extracorporeal treatment procedure in together with their patent pending process for treating ailments through the application of lasers.

The buzz

The methodology uses the concept of curing the blood outside the human body in a continuous flow procedure, together with an emissive energy means, such as a laser, to destroy directed antigens in the blood, before returning the blood to the person. The firm has exceptional privileges to three dispensed patents, one provisional patent application and six pending applications, all related to unique treatments for cancer as well as extracorporeal treatments for different life-threatening ailments.

Dr. Felder, the Inventor of the underlying technologies, expressed that the application of lasers in conjunction with their extracorporeal treatment procedure is a thrilling concept, as it should eliminate any infectious ailment, without the probability of pathogen resistance, or the action of side effects from the therapy. It also has the prospect for being an efficacious and inexpensive treatment for septicemia — a major cause of death globally.

William A. Hartman, the CEO and President of Premier Biomedical, expressed that they consider this combination of their patented extracorporeal treatment procedure with their patent awaiting emissive energy ablation of directed antigens could pave a complete new chapter in the means diseases are cured. The efficacy and safety of treatment protocols for a broad range of ailments could be considerably improved.

Premier Biomedical marks as a research-based publicly traded firm that plans to develop and discover medical treatments for a broad range of ailments in humans. The company has obtained, through different license agreements, the know-how behind three allowed US Patents, several pending provisional patents, as well as a ‘PCT’ Europe National Patent. Premier Biomedical was established back in 2010.

Continue Reading
Advertisement
Advertisement

TRENDING STORIES

INDUSTRIAL HEMP2 months ago

Digipath Inc. (OTCMKTS: DIGP) Announce Significant Milestones On Development Of GroSciences Hemp-Test Kit

Post Views: 328 Digipath Inc. (OTCMKTS:DIGP) has announced that its GroSciences subsidiary has made substantial progress in the development of...

INDUSTRIAL HEMP2 months ago

Harvest Health & Recreation Inc (OTCMKTS:HRVSF) Launches Expands Its Footprint In Florida With New Medical Marijuana dispensary in Gainesville

Post Views: 361 Harvest Health & Recreation Inc (OTCMKTS:HRVSF) recently announced that it launched a new outlet in Gainesville, making...

INDUSTRIAL HEMP2 months ago

Harvest Health & Recreation Inc (OTCMKTS:HRVSF) Gets Greenlight To Expand Its Foreign Private ISSUER Threshold

Post Views: 331 Harvest Health & Recreation Inc (OTCMKTS:HRVSF) revealed earlier this month that its Board of Directors has approved...

INDUSTRIAL HEMP2 months ago

Generex Biotechnology Corporation (OTCMKTS:GNBT) Adds MediSource Partners And Pantheon Medical To Its NuGenerex Family Of Subsidiaries

Post Views: 289 Generex biotechnology Corporation (OTCMKTS:GNBT) has welcomed MediSource Partners to its family of subsidiaries and introduced Pantheon Medical...

INDUSTRIAL HEMP2 months ago

CBD Unlimited Inc. (OTCMKTS:EDXC) Enhances Its Convenience Store Program Targeting 300 Stores

Post Views: 277 CBD Unlimited Inc. (OTCMKTS:EDXC), formerly Endexx Corporation, has announced an enhanced convenient store launch program. The provider...

INDUSTRIAL HEMP2 months ago

Cronos Group Inc. (NASDAQ:CRON) Spends $300 Million On CBD Skincare Businesses

Post Views: 264 Cronos Group Inc. (NASDAQ:CRON) has not had the best of runs in recent months, after starting the...

INDUSTRIAL HEMP2 months ago

Elev8 Brands, Inc. (OTCMKTS:VATE) A Potential Break Out Play On Sales Growth Boost

Post Views: 278 Elev8 Brands, Inc. (OTCMKTS:VATE) stock is a potential break out play as a flurry of positive developments...

INDUSTRIAL HEMP2 months ago

Medical Marijuana Inc. (OTCMKTS:MJNA) Eyes Fresh Gains On Improving Fundamentals

Post Views: 175 Medical Marijuana Inc. (OTCMKTS:MJNA) bounce back from all-time lows continues to gather pace on improving fundamentals. Investor’s...

INDUSTRIAL HEMP2 months ago

Sugarmade Inc. (OTCMKTS:SGMD) Turns To Hemp Production To Reinvigorate Growth Prospects

Post Views: 180 Sugarmade Inc. (OTCMKTS:SGMD) has made a strategic investment in Hempistry as it tries to reinvigorate its growth...

INDUSTRIAL HEMP9 months ago

Auxly Cannabis Group Inc (OTCMKTS:CBWTF) Acquires 46% Stake In Curative Cannabis And Agrees to Fund Cannabis Cultivation Facility To Produce Ultra Premium Cannabis

Post Views: 181 Auxly Cannabis Group Inc (OTCMKTS:CBWTF) has entered a deal to take over a 46% stake in Curative...

Advertisement

Whats Hot

CULTIVATING

SHAREHOLDER VALUE

 

Trading Symbol

CSE: CHOO
OTCQB: CHOOF

Choom Holdings Inc. CSE: CHOO | OTCQB: CHOOF